Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Medicine, Internal medicine, Oncology, Panobinostat, Clinical trial, and Gemtuzumab ozogamicin.
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of <i>KMT2A</i>-r and <i>NPM1c</i> AML
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy
A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
Sorafenib treatment following hematopoietic stem cell transplant in pediatric <i>FLT3</i>/ITD acute myeloid leukemia
A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia
High <i> <scp>EVI</scp> 1 </i> expression is associated with <i> <scp>MLL</scp> </i> rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group